Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions

Clement, Philip B.

doi:10.1038/modpathol.3800313

Cited by 49 publications

(45 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They grow very aggressively and the majority of patients present with advanced stages above stage IA and die rapidly (within 6 months). Potential prognostic factors excepted the disease stage (stage IA versus others) are age >30 years, a normal pre-operative calcium level, a tumor size <10 cm, the absence of large cells, surgical resection including bilateral oophorectomy and post-operative radiotherapy for some cases [7].…”

Section: Resultsmentioning

confidence: 99%

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type

Pautier¹,

Ribrag²,

Duvillard³

et al. 2007

Annals of Oncology

View full text Add to dashboard Cite

Background:The evaluation of first-line intensive combination therapy in small cell carcinoma of the ovary (SCCO). Patients and methods: Debulking surgery; four to six cycles of chemotherapy with cisplatin (P) 80 mg/m 2 day 1, adriamycin (A) 40 mg/m 2 day 1, vepeside (V) 75 mg/m 2 /day days 1-3, cyclophosphamide (EP) 300 mg/m 2 /day days 1-3, every 3 weeks and granulocyte colony-stimulating factor with, in case of a complete remission, high-dose chemotherapy with carboplatin, vepeside, cyclophosphamide and stem-cell support.Results: Twenty-seven patients (median age 25 years); International Federation of Gynecology and Obstetrics stage:five I, four IIC, 17 IIIC-IV and one unknown. Twenty patients underwent complete surgery. Eight patients progressed under chemotherapy. Among 18 patients in complete response (CR), 10 received high-dose chemotherapy (CT) (three stem-cell collection failures, two protocol violations, two disease progression and one refusal). The main grade 3-4 toxic effects were hematologic. There were eight relapses among the 18 CR, four of which were pelvic alone. Among the 27 patients, 13 died and 10 patients are in CR1, three in CR2. The median follow-up is 37 months (8-166) and the median duration of the 18 CR is 30 months (5-111). Overall survival at 1 and 3 years is 58% [confidence interval (CI) 40% to 75%] and 49% (CI 30% to 67%).Conclusions: Initial dose-intensive therapy achieves interesting overall survival in SCCO.

show abstract

Section: Resultsmentioning

confidence: 99%

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type

Pautier¹,

Ribrag²,

Duvillard³

et al. 2007

Annals of Oncology

View full text Add to dashboard Cite

show abstract

“…After a staging scan, early cases are managed with staging procedures including laparotomy as for epithelial ovarian cancers; and occasionally an unexpected diagnosis of SCCO is made at histology. However, in cases of extensive disease in a younger woman with an atypical pattern of metastasis, small cell carcinoma should be considered [1,3,[6][7][8][9][10][11][14][15][16]. More recently, PET-CT imaging may have a role in highly selected patients to take advantage of the aggressive metabolic pattern [28,29].…”

Section: Discussionmentioning

confidence: 99%

Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature

2010

View full text Add to dashboard Cite

Small cell carcinomas of the ovary (SCCO) are rare and aggressive malignant neoplasms carrying a poor prognosis. Although multi-modality treatment including chemotherapy leads to a high initial response rate, the majority of these patients relapse quickly and die within 2 years of diagnosis. Because these tumours are rare, there is no consensus to support any particular approach to management. We present 2 cases and review the relevant literature to make a number of recommendations. The treatment of these unusual cases should to be individually discussed in a multi-disciplinary team and multi-modality treatment including surgery, chemotherapy and radiotherapy should be considered for patients with limited disease. Conservative, fertility-preserving surgery may be considered in younger women with early-stage disease. Induction chemotherapy with weekly dose-dense and dose-intense carboplatin and taxane is useful. Prophylactic cranial irradiation (PCI) may be considered in patients in remission after primary treatment with chemotherapy or surgery.

show abstract

“…Furthermore, there are no determinant histological criteria for evaluation. Thus, there are some reports that they can be identified on the basis of criteria similar to those used for uterine smooth muscle tumors (2)(3)(4)(5).…”

Section: Discussionmentioning

confidence: 99%

“…However, there are no histological criteria for evaluating them. Currently, the histological criteria used to evaluate the smooth muscle tumors of uterus are applied to ovary (2)(3)(4). Those tumors are uncommon tumors that exhibit varied histological patterns, and there is discordance between their morphologic features (mitotic index, coagulative tumor cell necrosis, and atypia) and clinical outcomes.…”

Section: Introductionmentioning

confidence: 99%

A huge ovarian smooth muscle tumor: a case report

Murakami¹,

Uehara

Nishimura

et al. 2010

J. Med. Invest.

View full text Add to dashboard Cite

Selected miscellaneous ovarian lesions: small cell carcinomas, mesothelial lesions, mesenchymal and mixed neoplasms, and non-neoplastic lesions

Cited by 49 publications

References 65 publications

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type

Results of a prospective dose-intensive regimen in 27 patients with small cell carcinoma of the ovary of the hypercalcemic type

Dose-dense and dose-intense chemotherapy for small cell ovarian cancer: 2 cases and review of literature

A huge ovarian smooth muscle tumor: a case report

Contact Info

Product

Resources

About